| Pharmaceutical Information |
| Drug Name |
Conivaptan |
| Drug ID |
BADD_D00526 |
| Description |
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). |
| Indications and Usage |
For the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients. |
| Marketing Status |
approved; investigational |
| ATC Code |
C03XA02 |
| DrugBank ID |
DB00872
|
| KEGG ID |
D07748
|
| MeSH ID |
C106389
|
| PubChem ID |
151171
|
| TTD Drug ID |
D0VU2X
|
| NDC Product Code |
Not Available |
| UNII |
0NJ98Y462X
|
| Synonyms |
conivaptan | 4''-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide | (1,1'-biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)- | YM 087 | YM087 | conivaptan hydrochloride | (1,1'-biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-, monohydrochloride | Vaprisol |
|
| Chemical Information |
| Molecular Formula |
C32H26N4O2 |
| CAS Registry Number |
210101-16-9 |
| SMILES |
CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
